tralfaz, Be bullish, be confident but don't be blinded.
Recent UNS announcement headline
"Unilife Signs Long-Term Supply Contract with Sanofi for the Use of Unifill® Syringes with Lovenox®"
"Unilife to receive a minimum of $5 million and up to $15 million in milestone-based payments"
Then in the body of the release, "In addition to future revenue from the sale of Unifill Finesse syringes, Unilife may receive up to $15 million from Sanofi in milestones based payments with $5 million of these payments expected in 2013".
Even the $5mil minimum claim doesn't sit right with me, as the wording clearly states "expected".
Sanofi and UNS have been bed partners before;
"Unilife and sanofi-aventis Agree to Exclusivity List for Unifill™ Ready-to-Fill Syringe" 3rd March 2010.
What benefit was delivered to UNS shareholders from that agreement?
